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11 FOCOS Orthopaedic Hospital, Accra, Ghana BACKGROUND CONTEXT: Three-column osteotomies are frequently used in the correction of severe spinal deformities. However, these can be associated with high complication rates and significant risk for neurologic injury. Preoperative traction is one modality that has been used by surgeons to obtain a partial correction prior to definitive fusion. Low numbers and variability of traction protocols, however, have limited previous reports of outcomes of sustained preoperative traction. PURPOSE: We describe a novel halo-gravity traction (HGT) protocol for patients with severe spinal deformities in West Africa, and assess the clinical and radiographic outcomes. STUDY DESIGN/SETTING: Retrospective case series. PATIENT SAMPLE: 29 consecutive pediatric patients with severe spinal deformity. OUTCOME MEASURES: Radiographic measurements and SRS-22 scores obtained pre-traction, post-traction, and 6 weeks postoperatively. METHODS: All patients who underwent HGT prior to deformity surgery in Ghana from 4/2012 to 8/2013 were reviewed. HGT was started at 20% and increased by 10% per week until 50% of body weight was reached by 4 weeks. Traction was maintained in a wheelchair, walker and in bed except for meals and personal hygiene. Xrays were obtained pre-traction, every 4 weeks in traction, and at 6 weeks post-op. Demographic variables, operative data, radiographic parameters, and HRQL scores were collected. A deformity reduction index (DRI) was calculated at each time point by summing the scoliosis and abnormal kyphosis for each patient and reported as a percentage of the preoperative deformity. RESULTS: 29 patients underwent HGT for an average 107 days (range 58-179) prior to definitive posterior spinal fusion (24 patients) or placement of growing rods (5 patients). The major curve improved from 131 to 90 (31%) after HGT, and to 57 (56%) postoperatively. HGT was equally effective in correcting both scoliosis and kyphosis in patients with biplanar deformities, even after adjusting for curve flexibility. Pure kyphotic curves were rigid (flexibility 22% after traction), with a correction index (% postop curve correction/% flexibility) of 3.88, which is similar to historical controls (Lenke et al, Spine, 2009 ). Deformity correction with HGT plateaued at 63 days. SRS-22 scores improved significantly pretraction (3.5) versus postop (4.5), but there was no change post-traction (3.9) versus pretraction (3.5). There were 11 pin tract infections, with no neurological complications. CONCLUSIONS: Halo-gravity traction is a safe method to partially correct severe spinal deformities prior to a definitive procedure. It may obviate the need for higher risk 3-column osteotomies to achieve optimum correction. A prospective study is underway to determine which specific curve types are most amenable to preoperative traction. (71613 years) with 41 osteolytic vertebral bodies, who received KIVA with low viscosity PMMA and 24 patients (70611 years) with 43 vertebral body osteolyses, who were reinforced with BK and high viscosity PMMA. All osteolyses were grades as Tomita 1 to 3. Anterior (AVBHr), posterior (PVBHr), and middle vertebral body height ratio (MVBHr), Gardner kyphotic deformity, PMMA leakage and were measured and compared between the groups. VAS and ODI were used for functional outcome evaluation. RESULTS: No patient survived after 3 months. Asymptomatic PMMA leakage occurred in 4 (9.3%) vertebrae in the BK group solely (2 to the spinal canal, in Tomita grade 3 osteolysis). AVBHr , PVBHr and MVBHr and Gardner angle improved insignificantly similarly, in both groups. VAS and ODI improved postoperatively in both groups (P!0.001). CONCLUSIONS: BK and KIVA provided equally significant spinal pain relief in cancer patients with osteolytic metastasis. The absence of cement leakage in the KIVA group and absence of neurological complication in BK leakages reflects the safety of both augmentation techniques even in significant osteolysis. The lack of cement leakage in the KIVA cases, although low viscosity PMMA was used, increases this implant safety in augmenting severely destructed thoracolumbar vertebrae and sacrum from osteolytic metastasis. BACKGROUND CONTEXT: Some say, ''There's no place in spinal tumor surgery for minimally invasive approaches.'' Minimally invasive approaches can reduce morbidity, mitigate instability by avoiding removal of structures providing stability but result in removal of tumor causing compression, allow for correction of deformity, and provide lasting benefit for the patient without large incisions, use of extensive spinal instrumentation (which also degrades postoperative imaging), and high-blood-loss procedures that can result in significant morbidity and even mortality. PURPOSE: Our series of patients with symptomatic metastatic spinal compression (MESCC) treated with minimally invasive spinal (MIS) decompression, with or without vertebrectomy and vertebral body reconstruction, was reviewed retrospectively to determine whether these techniques can be beneficial in the treatment of symptomatic spinal metastases. STUDY DESIGN/SETTING: An IRB-approved retrospective review was performed on patients with a tissue-proven diagnosis of cancer and MRI evidence of metastatic epidural spinal cord compression (MESCC), treated in a multidisciplinary spine tumor practice at an academic center, and who underwent minimally invasive spinal decompression, either prior to or subsequent to other adjuvant treatments. Patients with multiple (more than two) levels of ventral spinal cord compression, severe instability that would require instrumentation even without any decompressive procedures, refused surgical intervention, or failed to obtain medical clearance for surgical intervention were excluded. PATIENT SAMPLE: Forty-three patients were identified, but 13 were excluded due to multiple levels, no confirmation of tumor at the site, or no decompression performed (biopsy only). Thirty patients were included and followed until death or current date. OUTCOME MEASURES: Length of stay and time to ambulation in those capable of ambulation. Numerous anatomical factors (including ratio of average spinal canal AP diameter above and below the index level of compression to the diameter of the residual canal at the level of worst compression, vertebral body height measurements at various points on the midline, and Cobb angle) as well as numerous previously validated functional scores (Hauser ambulation score, Karnofsky score, survival). Outcomes of patients who underwent this type of spinal operation were measured before the operation, immediately after the operation and at 1 month after the operation. METHODS: All patients underwent, after preoperative evaluation and imaging, a paramedian incision and a tubular dilator facilitated minimally invasive approach to hemilaminectomy with or without transpedicluar or costotransversectomy for vertebrectomy, and direct cement vertebroplasty or vertebral body replacement with poly-methyl methacrylate (PMMA) cement and closure with commercially available cyanoacrylate skin adhesive rather than sutures or staples. Length of stay and time to ambulation, in those capable of ambulation, was measured from the hospital records. Postoperative imaging was obtained in all patients. RESULTS: Thirty patients underwent 32 initial procedures with an average surgical time of 2:50 hours and average blood loss of 560 cc. Average AP canal diameter improved from 82.9% of baseline, to 93.1%. Those able to walk preop were unchanged from baseline, but those unable to ambulate preop improved significantly from a mean Hauser score (1-9, 1 is intact, 9 is no significant motor function) of 8.6 to 7.0 after the operation and to 6.4 at one month. Four of the eight in the poor ambulating group improved an average of 3.5; the other 4 had no significant change, and ambulation typically occurred by day 2 after surgery. Mean survival was 496 days-1.62 years for patients with good ambulation, 0.57 years with poor ambulation. There were 5 deaths in the first 30 days, no wound infections, and no deep venous thromboses (DVT) or pulmonary emboli in the postoperative period. Hospital stay averaged 6.7 days prior to discharge or transfer to rehab (in 1/3 of patients 3 days or less). Seven patients underwent 14 additional minimally invasive procedures. Six of seven first reoperations were for index level local recurrences. The average time between surgeries for recurrence was 182 days. Early first recurrences (less than 4 months) had the shortest survival time, (142 days vs. 839 days). CONCLUSIONS: Minimally invasive surgical treatments for MESCC can result in short procedures, rapid mobilization, short hospital stay, low rates of wound and other postoperative complications, potential improvement in ambulation status even for those with the worst exams. Long-term survival and longevity of neurological function can be maintained in this population with repeat procedures when necessary. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs. 26.7/16.5) . One average, the patients' ODI score improved 8.6 points at the latest follow up (range 3-18 months). For S2AI fixation with robotic guidance, patient mean age was 62 years (range 49-75) and 11 patients were female. Thirteen surgeries (87%) were revision surgeries. The mean levels instrumented were 1164. There were 3 dural tears (20%) intraoperatively and no other intraoperative complications or difficulties with the robotic guidance were encountered. The patients' mean length of stay was 964 days. All cause morbidity and mortality occurred in 8 patients at an average of 8 months follow-up including one mortality due to arrhythmia. Mean radiographic changes were (preop/postop): SVA 24.2 mm (100.4/76.2), TK 13.9 (28.4/42.3), LL 9.4 (21.9/31.3), PI 7.9 (52/59.9), SS 7.6 (22.9/30.5), PT 0.6 (28.6/29.2). On average, the patients' ODI score improved 15.1 points, back pain VAS improved 4.1 points, leg pain VAS improved 3 points at the latest follow up (range 3-13 months). CONCLUSIONS: S2AI fixation was more common in revision surgeries and no technique difficulties were encountered with O-arm/Stealth navigated or robotic guided S2AI fixation in this series. At shortterm followup, the patients in these two groups had similar all cause complication rates and clinical outcome. FDA DEVICE/DRUG STATUS: O-arm/Stealth navigation system (Approved for this indication), RenaissanceÔ robotic guidance system (Approved for this indication)
